Introduction {#s0005}
============

Prostate cancer (PC) is the most common male-specific malignancy in the developed world [@bb0005]. The disease progresses with a heterogeneous path. A large proportion of the low-grade \[Gleason score 6/WHO grade (group) I\] tumors are indolent. Approximately 30% of patients after radical prostatectomy (RP) will experience a rise in serum prostate-specific antigen (PSA) [@bb0010]; this biochemical recurrence (BR) significantly increases risk of PC metastasis and the development of castration-resistant prostate cancer (CRPC) [@bb0015]. PC predominantly metastasizes to the bone [@bb0020]; the standard treatment for this condition is androgen deprivation therapy (ADT). The treatment is palliative, and patients eventually develop CRPC. Although the recent developments have resulted in three sets of mRNA-based signatures, Oncotype DX (Genomic Prostate Score/GPS), Prolaris, and Decipher (Genomic Classifier), that evaluate the risk of PC progression [@bb0025], [@bb0030], [@bb0035], our ability to stratify PCs with high risk of progression remains poor. It is therefore critical to improve our understanding of factors contributing to PC recurrence, metastasis, and CRPC.

Mucin 1 (MUC1) is the most thoroughly studied tumor-associated antigen [@bb0040], [@bb0045], [@bb0050]. This is a cell membrane glycoprotein expressed on the apical surface of most epithelial tissues, including the pancreas, breast, lung, and gastrointestinal tract [@bb0055], [@bb0060]. The expression plays a protective role for the mucosal epithelial surface [@bb0065]. This polarity of apical presence in epithelial cells is lost in cancer cells; MUC1 is upregulated and altered in its pattern of glycosylation in over 70% of cancers [@bb0045], [@bb0055]. In PC, elevations in the MUC1 protein and aberrant MUC1 glycosylation have been observed [@bb0070], [@bb0075], [@bb0080]. These changes are associated with increases in angiogenesis [@bb0085], adverse clinical features, and higher Gleason scores [@bb0090]. MUC1 upregulation is weakly related with reductions in disease-free survival (DFS) and overall survival (OS) [@bb0090] and associates with adverse histopathology after RP [@bb0095]. A panel of three proteins (AZGP1, MUC1, and p53) predicts death in men with local PC [@bb0100]. Increases in MUC1 mRNA were observed in PC metastasis, genomic alterations in the *MUC1* gene were detected in CRPC, and genomic changes in a 25-factor MUC1 network marginally correlated with PC recurrence [@bb0105]. Collectively, MUC1's involvement in PC recurrence, metastasis, and CRPC development shows great potential that warrants further investigations.

In this study, we examined MUC1 expression in CRPC produced by xenografts and prostate-specific *PTEN*^*−/−*^ transgenic mice, and in patients with hormone-naïve PC metastasized to bone. We also determined the association of a MUC1 network with PC recurrence using the PC data sets within the cBioPortal database. We report here 1) a relationship of MUC1 upregulation with CRPC and PC bone metastasis and 2) a nine-gene signature that is strongly associated with PC recurrence.

Materials and Methods {#s0010}
=====================

Collecting PC Bone Metastasis {#s0015}
-----------------------------

Bone tissues containing metastatic PC were obtained from Hamilton Health Sciences, Hamilton, Ontario, Canada, under approval from the local Research Ethics Board (REB \#11-3472).

Generation of CRPC Using Animal Models {#s0020}
--------------------------------------

LNCaP cells (5 × 10^6^) were used to produce subcutaneous xenograft tumors in 8-week-old male NOD/SCID mice (The Jackson Laboratory); tumor volume was monitored according to our published systems [@bb0105]. Tumor growth was measured by serum PSA levels (PSA kit, Abcam). Mice were surgically castrated when tumor reached 100 to 200 mm^3^. Serum PSA was determined before and following castration. Rise in serum PSA indicates CRPC growth. Animals were sacrificed once tumors reached a volume ≥1000 mm^3^.

Prostate-specific *PTEN*^*−/−*^ mice were produced using *PTEN*^*loxp/loxp*^ (C;129S4-*Pten*^*tm1Hwu*^/J; the Jackson Laboratory) and PB-Cre4 mice \[B6.Cg-Tg(Pbsn-cre)4Prb, the NCI Mouse Repository\] following our published conditions [@bb0110]. Surgical castration was performed when mice were 23 weeks old and subsequently monitored for 13 weeks. All animal protocols were approved by the McMaster University Animal Research Ethics Board.

Quantitative Real-Time PCR Analysis of MUC1 Expression {#s0025}
------------------------------------------------------

Real-time PCR using RNA samples was performed as previously described [@bb0105], [@bb0110]. All samples were run in triplicate using the following primers: MUC1 (forward): 5′-TGCCGCCGAAAGAACTACG-3′, MUC1 (reverse): 5′-TGGGGTACTCGCTCATAGGAT-3′. β-actin (forward): 5′-ACCGAGCGCGGCTACAG-3′, β-actin (reverse): 5′-CTTAATGTCACGCACGATTTCC-3′.

Immunohistochemistry (IHC) {#s0030}
--------------------------

Slide preparation, processing, and antigen retrieval were carried out according to our established protocols [@bb0105], [@bb0110]. Slides were blocked in PBS, 1% BSA, and 10% normal goat serum (Vector Laboratories) for 1 hour. MUC1-N (N-terminus) (1:100, BD), MUC1-C (1:50, Fisher Scientific), and prostate acid phosphatase (PAP) (1:300, Abcam) antibodies were added at 4°C overnight. Biotinylated goat anti-mouse IgG or anti-hamster IgG secondary antibodies, and Vector ABC reagent (Vector Laboratories) were incubated according to the manufacturer\'s instructions. Secondary antibody only was used as negative control. Images were acquired and analyzed using ImageScope software (Leica Microsystems Inc.). Quantification of MUC1-positive PC cells was performed by counting up to 10,000 cells in several regions for MUC1-positve and PAP-positive cells. Percentage of MUC1-postive cells was estimated as MU1 positivity/PAP positivity × 100.

Establishing of a Nine-Gene Genomic Signature from the MUC1 Network {#s0035}
-------------------------------------------------------------------

The largest TCGA data set (*n* = 499), which includes 485 patients with follow-up data, within the cBioPortal database [@bb0115], [@bb0120] (<http://www.cbioportal.org/index.do>) was extracted and randomly divided into 10 sets of training (*n* = 300) and testing (*n* = 185) cohorts using the RandomizationR package in R. The 25 genes of the MUC1 network [@bb0105] plus FAM84B [@bb0110] ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}) were inputted into the Cox model to select for their contributions to hazard ratio (HR) by either forward addition or backward elimination of covariates using SPSS Statistics version 23. The resultant 9 genes were then examined on the 10 testing cohorts and validated on an independent cohort (MSKCC, cBioPortal, *n* = 194) for effects on DFS, OS, and HR using the Survival package in R.

Statistical analysis {#s0040}
--------------------

Statistical analysis was performed using Student\'s *t* test. Kaplan-Meier surviving curves, log-rank test, receiver-operating characteristic (ROC) curve, and univariate and multivariate Cox proportional hazards regression analyses (Survival package in R and SPSS Statistics version 23). A value of *P* \< .05 is considered statistically significant.

Results {#s0045}
=======

Upregulation of MUC1 in CRPC {#s0050}
----------------------------

CRPC is the leading cause of PC fatalities; specific genomic alteration in the *MUC1* gene was observed in CRPC [@bb0105]. To examine MUC1 expression in CRPC, we implanted LNCaP cells, a well-established androgen-dependent PC cell line, into NOD/SCID mice. Surgical castration initially reduced tumor growth, followed by a subsequent tumor regrowth ([Figure 1](#f0005){ref-type="fig"}*A*). The regrown tumors (CRPCs) exhibited a significant increase in MUC1 mRNA compared to the xenografts developed in intact mice ([Figure 1](#f0005){ref-type="fig"}*B*). Elevations in MUC1 protein in CRPC were also demonstrated; cell surface expression and a special clustering pattern for MUC1 were observed ([Figure 1](#f0005){ref-type="fig"}*C*), which is consistent with MUC1 being a cell surface protein [@bb0055], [@bb0060] and its detection in prostate cancer stem-like cells [@bb0105].Figure 1MUC1 upregulation in animal models of CRPC. (A) PSA levels in NOD/SCID mice bearing LNCaP cell-derived xenograft tumors prior to and after castration. (B) Real-time PCR analysis of MUC1 mRNA in hormone-naive (*n* = 3) and castration-resistant (*n* = 3) LNCaP xenograft tumors. Statistical analysis was performed using Student\'s *t* test (two-tailed). (C) IHC staining of MUC1 in LNCaP xenograft tumors produced in intact (*n* = 3) and castrated mice (*n* = 3). Typical images from three different regions of individual tumors are shown. The indicated regions were enlarged three-fold.Figure 1

Furthermore, we have generated prostate-specific *PTEN*^*−/−*^ mice ([Supplementary Figure 1](#f0035){ref-type="graphic"}*A*), castrated the animals at 23 weeks, and euthanized the mice 13 weeks later. CRPCs were clearly developed ([Supplementary Figure 1](#f0035){ref-type="graphic"}*B*). Compared to tumors in intact mice, tumors in castrated mice express an increased level of MUC1 ([Figure 2](#f0010){ref-type="fig"}). Intriguingly, the MUC1 protein shows a preference of expression in the luminal layer epithelial cells in mouse PINs produced in castrated *PTEN*^*−/−*^ mice ([Figure 2](#f0010){ref-type="fig"}), and this preference is lost in carcinoma ([Figure 2](#f0010){ref-type="fig"}), resembling the MUC1's expression pattern in nontumor [@bb0065] and tumor tissues [@bb0045], [@bb0055]. Collectively, we provide direct evidence for MUC1 upregulation in CRPC.Figure 2Increases in MUC1 expression in CRPC generated from prostate-specific *PTEN*^*−/−*^ mice. Generation of prostate-specific *PTEN*^*−/−*^ mice is detailed in Supplementary Figure 1. *PTEN*^*−/−*^ mice were castrated at 23 weeks old and monitored for 13 weeks, followed by IHC straining for MUC1. Typical images of MUC1 staining in intact (*n* = 3) and castrated (*n* = 3) mouse prostate. The indicated regions were enlarged three-fold. Note: MUC1 is largely detected in the luminal surface of mouse PINs in castrated mice. mPIN, mouse PIN.Figure 2

Extensive Expression of the MUC1 Protein in Hormone-Naïve PCs Metastasized to the Bone {#s0055}
--------------------------------------------------------------------------------------

Metastasis to the bone is a major cause of morbidity in patients with PC. We recently observed increases in MUC1 mRNA in metastatic PCs [@bb0105]. To examine the MUC1 protein in PC metastasized to the bone, we obtained nine bone biopsy samples from patients who presented with PC metastatic to bone at diagnosis; the tumors were thus hormone naïve ([Table 1](#t0005){ref-type="table"}). The metastatic prostate origin was confirmed by prostate acid phosphatase (PAP) staining, a widely used surrogate marker of PC cells in the clinic. Based on PAP-positive cells, extensive MUC1 expression in PC cells was demonstrated ([Figure 3](#f0015){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}). A good coordinate expression of MUC1 detected by antibodies against MUC1 N- and C-terminus was observed ([Supplementary Figure 2](#f0040){ref-type="graphic"}). Collectively, we show the first evidence for extensive MUC1 expression in hormone-naïve PC bone metastasis in humans. These observations are novel and clinically significant (see Discussion for details).Figure 3Extensive expression of MUC1 in PC-derived bone metastases from hormone-naïve patients. Bone tissues with hormone-naïve PC were obtained from patients \#3 and \#4 and were IHC stained for PAP and MUC1 using an antibody to a MUC1 N-terminal region. Matched images of a low magnification for PAP and MUC1 staining are shown (top panels). Regions marked with the same number in the PAP and MUC1 image of individual patients are matched. Please note that the \#2 region in the PAP image of patient 4 was dislocated during IHC staining. Matched images of PAP and MUC1 staining for patient \#3 in a higher magnification are also included (bottom panel).Figure 3Table 1MUC1 Expression in Bone Metastases of PC Derived from Hormone-Naïve Patients[a](#tf0005){ref-type="table-fn"}Table 1PatientAge[b](#tf0010){ref-type="table-fn"}PSA[c](#tf0015){ref-type="table-fn"}Hormone StatusMUC1/PAP (%)[d](#tf0020){ref-type="table-fn"}27126Naive0[e](#tf0025){ref-type="table-fn"}377522Naive89.6%481649Naive84.1%661205Naive64.8%97121Naive61.1%108010Naive100%1173164Naive74.8%126234Naive97.8%1372163Naive75.7%[^2][^3][^4][^5][^6]

Derivation of a Nine-Gene Signature from a MUC1 Network with a Robust Predicting Value of PC Recurrence {#s0060}
-------------------------------------------------------------------------------------------------------

BR is associated with significant increases in risk for PC metastasis and CRPC [@bb0015]. Despite extensive research effort searching for BR-associated biomarkers, effective biomarkers are not available. Our observed MUC1 upregulation in CRPC and bone metastasis suggests a relationship between MUC1 and BR. Indeed, a weak association of MUC1 and PC recurrence was recently reported [@bb0090]; MUC1 associates with adverse pathology after RP [@bb0095]; and MUC1 along with AZGP1 and p53 predicts death in patients with local prostate tumor [@bb0100]. We reasoned that our recently identified MUC1 network consisting of 25 genes [@bb0105] would enhance the effectiveness of BR prediction.

To address this possibility, we extracted a population (*n* = 485) with genomic alterations and pathological data from the TCGA data set (*n* = 499) within the cBioPortal database. Ten random sets of training (*n* = 300) and testing (*n* = 185) cohorts were generated ([Table 2](#t0010){ref-type="table"}). FAM84B is a novel factor associated with PC progression [@bb0110]. A systematic variable selection from the 25 genes of the MUC1 network ([Supplementary Figure 3](#f0045){ref-type="graphic"}) and FAM84B for their specific genomic alterations ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}) using the Cox model yielded 16 candidate genes ([Table 3](#t0015){ref-type="table"}). The top eight genes appeared in at least two training cohorts ([Table 3](#t0015){ref-type="table"}); LYN and GALNT15 have *P* values approaching the significant level (*P* \< .05) and HR \> 1 ([Table 3](#t0015){ref-type="table"}); the top eight genes (GALNT10, SOS1, ZAP70, FAM84B, GRB2, SIGLEC1, CTNNB1, and APC) plus LYN and GALNT15 ([Table 3](#t0015){ref-type="table"}) were thus further considered. The 95% confidence interval (CI) for GALNT15 was large ([Table 3](#t0015){ref-type="table"}); its removal from this 10-gene list improved HR and *P* values in 6 training cohorts ([Supplementary Table 2](#ec0010){ref-type="supplementary-material"}). We thus defined the nine-gene signature for their specific genomic alterations ([Table 3](#t0015){ref-type="table"}).Table 2Demographics of Patient PopulationsTable 2CharacteristicsTraining Set[a](#tf0030){ref-type="table-fn"} (*n* = 300)Testing Set[a](#tf0030){ref-type="table-fn"} (*n* = 185)Age (years) Mean median ± SD61.2 ± 0.461.5 ± 0.67 Q1(SD)-Q3(SD)56.1 (0.32)-65.9 (0.3)56.3 (0.64)-66 (0.63)Follow-up (months) Mean median ± SD27 ± 1.3327.2 ± 2.07 Q1(SD)-Q3(SD)14.7 (0.7)-45.1 (1.2)14 (1.5)-44.5 (2.1)Recurred No (mean ± SD, %)245.5 ± 4.8, 82%149.5 ± 4.8, 81% Yes (mean ± SD, %)53.5 ± 4.8, 18%35.5 ± 4.8, 19%Tumor stages T2a (mean ± SD, %)7.7 ± 2, 2.6%5.3 ± 2, 2.9% T2b (mean ± SD, %)5.5 ± 1.2, 1.7%1.8 ± 1.2, 1% T2c (mean ± SD, %)102.1 ± 4.2, 34%61.9 ± 4.2, 33.5% T3a (mean ± SD, %)94.7 ± 2.8, 31.6%60.4 ± 2.8, 32.6% T3b (mean ± SD, %)81.6 ± 5.4, 27.2%48.4 ± 5.4, 26.2% T4 (mean ± SD, %)5.7 ± 1.3, 1.9%4.3 ± 1.3, 2.3%Surgical margin R0 (mean ± SD, %)188 ± 4.5, 62.7%121 ± 4.5, 65.4% R1 (mean ± SD, %)90.8 ± 4.2, 30.3%51.2 ± 4.2, 27.7% R2 (mean ± SD, %)2.5 ± 0.7, 0.8%2.2 ± 0.8, 1.2% Rx (mean ± SD, %)9.8 ± 2.6, 3.3%5.2 ± 2.6, 2.8%[^7]Table 3Candidate Genes Selected Using the Training SetsTable 3GeneGen Alt[a](#tf0035){ref-type="table-fn"}HR[b](#tf0040){ref-type="table-fn"}95% CI[b](#tf0040){ref-type="table-fn"}*P* Value[b](#tf0040){ref-type="table-fn"}Frequency[c](#tf0045){ref-type="table-fn"}GALNT10[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut5.1771.269-21.311.022\*4SOS1[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut235.181-98.222\<.0001\*10ZAP70[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut4.5241.765-11.598.002\*5FAM84B[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp2.2361.053-4.746.036\*2GRB2[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut7.6961.031-57.462.047\*3SIGLEC1[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut6.461.98-21.074.002\*4CTNNB1[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut6.5531.883-22.808.003\*5APC[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Homdel Mut3.0841.2-7.924.019\*5LYN[d](#tf0050){ref-type="table-fn"}, [e](#tf0055){ref-type="table-fn"}Amp Mut2.5350.993-6.471.0521GALNT15[d](#tf0050){ref-type="table-fn"}7.6451.013-57.701.049\*1ERBB22.4640.614-9.889.2031CTNND16.1390.839-44.933.0742GALNT21.7760.536-5.888.3481MUC10.3650.037-3.597.3881JUP0.0170.009-0.586.024\*1ABL100-0.00501[^8][^9][^10][^11][^12]

Reanalysis of the 9-gene signature revealed a robust association with reductions of DFS in all 10 training cohorts (smallest *P* = 6.11e-7) and 8 of 10 testing cohorts (smallest *P* = 5.75e-5) ([Figure 4](#f0020){ref-type="fig"}, data not shown). Of note, the 9-gene signature was a risk factor for BR in all training and 8 of 10 testing populations based on HR ([Supplementary Table 3](#ec0015){ref-type="supplementary-material"}). The signature was not associated with reductions in DFS (data not shown), and neither was it a risk factor in the same two testing cohorts ([Supplementary Table 3](#ec0015){ref-type="supplementary-material"}), which likely resulted from patient randomization. It is thus important to use multiple sets of randomized training and testing cohorts. We further examined this nine-gene signature in the entire TCGA cohort (*n* = 492) ([Figure 5](#f0025){ref-type="fig"}*A*) and demonstrated its robust association with decreases in DFS ([Figure 5](#f0025){ref-type="fig"}*B*). This association was also revealed in an independent cohort of primary PC (*n* = 194) (cBioPortal) [@bb0125] ([Figure 5](#f0025){ref-type="fig"}, *C* and *D*). Furthermore, among the 9 PC-related fatalities in the TCGA population (*n* = 491; 9/491 = 1.8%), 5 were in the 9-gene signature-positive population (*n* = 100; 5/100 = 5%; *P* = .0271) ([Figure 5](#f0025){ref-type="fig"}*E*). Additionally, the 9-gene signature is also detected in a patient population of cutaneous melanoma (*n* = 367) (TCGA, cBioPortal) ([Figure 6](#f0030){ref-type="fig"}*A*) and associates with reductions in OS and DFS in these patients ([Figure 6](#f0030){ref-type="fig"}, *B* and *C*).Figure 4The nine-gene signature associates with reductions in DFS in training and testing cohorts. See [Table 3](#t0015){ref-type="table"} for the identities of nine genes and the types of genomic alterations being tested in the signature. The signature was evaluated in 10 individual sets of training and testing populations; typical results in 2 cohort sets are shown. Kaplan-Meier and log-rank tests were performed using the R Survival Package. Recurr, recurrence; T, total. For training cohort, *n* = 300; for testing cohort, *n* = 185.Figure 4Figure 5The nine-gene signature robustly correlates with decreases in DFS and OS in PC. (A) The indicated types of genomic alterations for the nine genes in the TCGA data set (*n* = 492) within the cBioPortal database [@bb0115], [@bb0120] are shown; only the proportion of cohorts containing the nine-gene signature are included. Each column is for individual tumor. Note: This cohort was used to generate the training and testing subcohorts. DF, disease free; NA, not available. (B) Analysis of DFS using the TCGA cohort. Total\#, total number of cases; relap\#, number of relapsed cases; MMDFS, median months disease-free survival. (C, D) Genomic alterations for the nine genes in a subcohort (*n* = 194) within a MSKCC data set (cBioPortal) [@bb0125] (C) and the effects of the nine-gene signature on DFS in this cohort (D). (E) Analysis of patients with the nine-gene signature--positive or --negative tumors for their overall survival using the TCGA data set. Dec\#, number of deceased cases; MMS, median months survival.Figure 5Figure 6The nine-gene signature associates with reductions in DFS and OS in patients with cutaneous melanoma. Data were extracted from the TCGA data set of cutaneous melanoma within the cBioPortal database. Analysis of genomic alterations in the nine genes in the TCGA cohort (*n* = 367); the DF and survival status for these patients are also included (A). The nine-gene signature associates with a significant reduction in OS (B, *n* = 358) and DFS (C, *n* = 315) in these patients.Figure 6

Although the nine-gene list includes a non-MUC1 network member FAM84B, the eight-gene signature of the MUC1 network after removing FAM84B retains the core association with decreases in DFS and OS in PC and cutaneous melanoma ([Supplementary Figure 4](#f0050){ref-type="graphic"}, *A*-*C*). Comparing [Figure 5](#f0025){ref-type="fig"}*B* to [Supplementary Figure 4](#f0050){ref-type="graphic"}*A*, FAM84B clearly contributes to the association. Furthermore, removal of any individual gene from the nine-gene list decreased its association with shortening of DFS in PC (the TCGA cohort, cBioPortal; data not shown), validating their necessity in the signature set.

APC and β-Catenin Contributions to PC Recurrence {#s0065}
------------------------------------------------

The major type of genomic alterations detected in CTNNB1 (encoding β-catenin) was missense mutations ([Figure 5](#f0025){ref-type="fig"}*A*). We thus examined these mutations in details. cBioPortal contains nine independent PC populations; missense mutations in β-catenin were extracted from seven cohorts ([Table 4](#t0020){ref-type="table"}). T41A was found in six populations ([Table 4](#t0020){ref-type="table"}). In cohorts with follow-up data, T41A-positive tumors caused PC death (1 for 1, the Michigan cohort) and recurrence (1 for 2, the TCGA cohort) ([Table 4](#t0020){ref-type="table"}). Missense mutations at D32 were detected in four cohorts ([Table 4](#t0020){ref-type="table"}). Intriguingly, in the metastatic PC cohort of Michigan [@bb0130] with 100% fatality (*n* = 48), patients with the missense mutations in β-catenin had a rapid onset of death ([Supplementary Figure 5](#f0055){ref-type="graphic"}). The residues D32, S33, S37, T41, and S45 are within the destruction box of β-catenin and are required for β-catenin degradation, a process mediated by the degradation complex including APC, GSK-3β, and casein kinase 1α [@bb0135], [@bb0140], [@bb0145]. Missense mutations in these residues stabilize β-catenin, contribute to tumorigenesis, and occur in multiple tumor types, including D32Y, S33F, and T41A in PC [@bb0140], [@bb0150]. Nonetheless, we describe for the first time a set of missense mutations at D32, S33, S37, T41, and S45 in PC ([Table 4](#t0020){ref-type="table"}) and novel missense mutations detected outside of the destruction box [@bb0140], N387K, W383G, and R225H. These novel mutations are observed in tumors causing either PC death or recurrence ([Table 4](#t0020){ref-type="table"}). While whether all mutations described here promote PC progression remains unknown, their mutual exclusivity with genomic alterations of the APC tumor suppressor ([Figure 5](#f0025){ref-type="fig"}*A*), a well-demonstrated theme in colon cancer [@bb0140], suggests their contributions together with APC in PC recurrence. Indeed, we provide the first evidence that genomic alterations in APC and β-catenin significantly shorten DFS in the TCGA (*n* = 492, *P* = .0369) and MSKCC (*n* = 103, *P* = .0437) cohorts (cBioPortal) ([Supplementary Figure 6](#f0060){ref-type="graphic"}).Table 4β-Catenin Mutations in PC and Their Impact on PC Death and Recurrence.Table 4Patient Cohort*n*Mutation (*n*); PatientSurvival or RecurrenceMichigan, Nature 201259**T41A (1)**Deceased (OS 15 months)**D32**Y (1)Deceased (OS 69 months)N387 K (1)Deceased (OS 41 months)Robinson et al., Cell 2015150**T41A (2)**NAS37C (1)NAS45C (1)NAS45F (1)NAFH, Nat Med 201656**T41A (1)**NA**D32**V (1)NAM14 V;S37Y (1)NAS45P (1)NAM763I (1)NATrento/Cornell/Broad 201681**T41A (1**)NA**D32**N (1)NAS33A (1)NAMSKCC, Cancer cell 2010103A522T;S45PNAW383G (1)RecurredCPC-GENE, Nature 2017449**T41A (1)**NATCGA provisional489**T41A (1);** HC-7738[a](#tf0060){ref-type="table-fn"}Recurred, DF:13.8 months**T41A (1);** EJ-A65D[a](#tf0060){ref-type="table-fn"}DF, censored: 12.9 months**D32**Y (1), HC-8262[a](#tf0060){ref-type="table-fn"}DF, censored: 22.3 months**D32**V (1), EJ-5494[a](#tf0060){ref-type="table-fn"}DF, censored: 48.5 months**D32**H (1), EJ-5525[a](#tf0060){ref-type="table-fn"}Recurred, DF: 17.9 monthsS33A (1)DF; censored: 41 monthsS33Y (1)DF; censored: 21.8 monthsS33C (1)Recurred; DF: 18.4 monthsS45P (1)DFR225H (1)RecurredR342K (1)DFT75I (1)DF[^13][^14][^15][^16]

The Nine-Gene Signature Stratifies Patients with High Risk of PC Recurrence and Is an Independent Risk Factor for PC Recurrence {#s0070}
-------------------------------------------------------------------------------------------------------------------------------

To examine whether the nine-gene signature stratify patients with elevated risk in PC recurrence, we scored each patients based on their nine-gene signature using ∑(*f*~i~)~*n*~ (*f*~i~: Cox coefficient of gene~i~, *n* = 9) ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}). Scores derived from the signature have an AUC value of 0.64 (*P* = .002) in predicting PC recurrence ([Supplementary Figure 7](#f0065){ref-type="graphic"}*A*). The median (≥0.657) and Q3 (≥1.089) scores classify patients into high- and low-risk group of PC recurrence ([Supplementary Figure 7](#f0065){ref-type="graphic"}, *B* and *C*). While the 9-gene signature has DFS = 73.4 months (95% CI: 37.1-109.5, *P* = 5.557e-5), the median and Q3 scores ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}) show respective DFS = 63.2 months (95% CI: 23.2-103.2, *P* = 8.91e-5) and 29.4 months (95% CI: 3.5-55.2, *P* = 1.23e-5).

We further demonstrated the 9-gene signature being an independent risk factor for PC recurrence (HR = 1.731, 95% CI: 1.104-2.712, *P* = .0167) after adjusting for TMN tumor stage, age at diagnosis, radical prostatectomy (total) GS, and surgical margin ([Table 5](#t0025){ref-type="table"}). Instead of total GS, we also analyzed the World Health Organization (WHO) PC grading system \[WHO grade (group) I-V, see [Supplementary Table 4](#ec0020){ref-type="supplementary-material"} for details\]; the signature continues to predict PC recurrence (HR = 1.769, 95% CI: 1.130-2.768, *P* = .0126) after adjusting for the WHO grades, TMN tumor stage, age, and surgical margin. Of note, the high-risk group of patients stratified by the median and Q3 scores is associated with an elevated and independent HR = 2.07 (95% CI: 1.245-3.450, *P* = .0051)/total GS or HR = 2.054 (95% CI: 1.234-3.417, *P* = .0056)/WHO grades and HR = 3.707 (95% CI: 1.949-7.052, *P* = 6.51e-5)/total GS or HR = 3.832 (95% CI: 2.015-7.286, *P* = 4.18e-5)/WHO grades, respectively. Additionally, by performing similar analysis on the nine genes individually, we observed a general worsening in individual HR and *P* values in multivariate Cox analysis compared to univariate analysis only in the eight MUC1 network genes ([Supplementary Table 5](#ec0025){ref-type="supplementary-material"}), which validates the eight genes belonging to the MUC1 network.Table 5Univariate and Multivariate Cox Analysis of the Nine-Gene Signature for PC RecurrenceTable 5UnivariateMultivariateClinical Variables*n*[a](#tf0065){ref-type="table-fn"}HR95% CI*P* ValueHRCI (95%)*P* ValueThe 9-gene sig[b](#tf0070){ref-type="table-fn"} 0390 1952.3811.547-3.6843.47e-5\*1.7311.104-2.712.0167\*Tumor stage[c](#tf0075){ref-type="table-fn"} ≤ T2184 T3 and T42953.932.178-7.1025.57e-6\*1.9190.994-3.683.0502Age at diagnosis4851.0250.993-1.058.1281.0020.970-1.036.8879RP GS[d](#tf0080){ref-type="table-fn"}4852.2091.773-2.7521.57e-12\*1.8741.430-2.3601.93e-6\*Margin status[e](#tf0085){ref-type="table-fn"} 0208 11472.1621.418-3.296.00034\*1.2710.798-1.993.3203[^17][^18][^19][^20][^21]

In view of the recent demonstration with respect to increased prostate cancer risk in men with germline mutations in BRCA1 and BRCA2 [@bb0155], we reasoned whether there is a relationship between the nine-gene signature and these mutations. Somatic mutations in BRCA1 (1 in 492) and BRCA2 (7 in 492) are not a frequent event in the TCGA cohort ([Supplementary Figure 8](#f0070){ref-type="graphic"}). Of these mutations, the BRCA1 and three BRCA2 mutations co-occur with the nine-gene signature ([Supplementary Figure 8](#f0070){ref-type="graphic"}). Importantly, addition of BRCA1 and BRCA2 mutations (positive cases 102/recurred cases 32, median DFS months 73.36; negative cases 383/recurred cases 57, median DFS months not reached; *P* = 1.099e-4) does not enhance the 9-gene\'s predictive potency (positive cases 96/recurred cases 31, median DFS months 73.36; negative cases 389/recurred cases 58, median DFS months not reached; *P* = 5.575e-5). Collectively, these observations provide indirect support for the importance of the intercomponent connections in the association of the nine-gene signature with reductions in DFS.

Discussion {#s0075}
==========

MUC1 expression is commonly altered in multiple tumor types [@bb0045], [@bb0055], [@bb0060] and promotes tumor progression through activation of the EGFR, β-catenin, NF-κB, PKM2, and other pathways [@bb0045], [@bb0065], [@bb0160]. MUC1 thus has applications in diagnosis and therapy. However, both applications need further investigations.

We provide the first evidence for elevations of the MUC1 proteins in CRPC ([Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"}). Of note, a recent phase II clinical trial reported that a MUC1-based dendritic cells (DC) vaccination delayed PC progression in patients with nonmetastatic CRPC [@bb0165]. Our study provides further support for DC-MUC1 vaccine in treating CRPC.

We also observed for the first time the extensive expression of MUC1 protein in hormone-naïve PC metastasized to bone ([Figure 3](#f0015){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}). Our research thus strongly suggests that targeting MUC1 should be considered either as a monotherapy or in combination with ADT in treating patients with hormone-naïve bone metastasis.

We further pioneered a thorough investigation of MUC1's biomarker value in the context of a network setting, an effort supported by the need of multiple factors to effectively predict cancer progression. Our nine-gene signature associates robustly with PC recurrence. Currently, there are 3 sets of mRNA-based signatures to evaluate PC progression: the 17-gene Oncotype DX (GPS) [@bb0170], the 31-gene signature of CCP (cell cycle progression; Prolaris) [@bb0175], and the 22-gene Decipher signature [@bb0025], [@bb0030], [@bb0035], [@bb0180]. Adding to this resource is our novel nine-gene genomic signature. Interestingly, this signature also correlates with reductions in DFS and OS in patients with cutaneous melanoma ([Figure 6](#f0030){ref-type="fig"}).

In this signature, individual genes of the MUC1 network display overlaps or connections in association with PC recurrence evidenced by the worsening of their HR and *P* values in multivariate Cox analysis ([Supplementary Table 5](#ec0025){ref-type="supplementary-material"}). These connections explain why MUC1 is not present in the signature gene list, as the eight genes mediate the functional contributions of MUC1. This scenario is supported by the multiple processes covered by the eight MUC1 network genes in the nine-gene list ([Table 3](#t0015){ref-type="table"}), including tyrosine kinase signaling (LYN and ZAP70); signaling transduction (GRB2 and SOS1) [@bb0185]; protein glycosylation (GALNT10 and SIGLEC1), a process that contributes to PC progression [@bb0190]; and the Wnt pathway (APC and CTNNB1) ([Table 3](#t0015){ref-type="table"}).

Mutations in APC are mutually exclusive from those occurring in β-catenin in colon cancer [@bb0140]. Nonetheless, their contributions to PC recurrence remain unknown. We demonstrate here that genomic alterations in APC and β-catenin associate with PC recurrence ([Supplementary Figure 6](#f0060){ref-type="graphic"}). In addition to previously documented missense mutations located in the destruction box of β-catenin in PC, D32Y, S33F, and T41A [@bb0140], [@bb0150], we describe an array of missense mutations in D32, S33, S37, T41, and S45 in PC that has been reported in other tumor types, including hepatocellular carcinoma, colon cancer, ovarian cancer, medulloblastoma, uterine tumors [@bb0140], glomangiopericytoma [@bb0195], and desmoid-type fibromatosis [@bb0200], [@bb0205], [@bb0210]. T41A was detected in up to 64% of pediatric fibromatosis and contributes to the aggressiveness of the disease [@bb0215], [@bb0220]. Among three patients harboring T41A PC with follow-up data, two experienced disease progression ([Table 4](#t0020){ref-type="table"}); it is intriguing whether, with a longer follow-up period, patient EJ-A65D will have PC recurrence ([Table 4](#t0020){ref-type="table"}). It is thus tempting to propose a causative role of T41A in PC recurrence. Despite the fact that mutations in D32, S33, S37, T41, and S45 do not occur frequently in PC ([Table 4](#t0020){ref-type="table"}), other mechanisms may be present to compensate for these mutations. Additionally, three new β-catenin mutations were detected on residues outside of the destruction box, N387K, W383G, and R225H, and they occurred together with PC recurrence and fatality. Although the impact of all β-catenin mutations detected here ([Table 4](#t0020){ref-type="table"}) on PC oncogenesis needs additional studies, the observed mutual exclusiveness between APC mutations and β-catenin mutations strongly suggests their roles in PC promotion ([Table 4](#t0020){ref-type="table"}).

The following are the supplementary data related to this article.Supplementary Figure 1Production of CRPC in prostate-specific *PTEN*^*−/−*^ mice. (A) Prostate-specific *PTEN*^*−/−*^ mice were produced by crossing *PTEN*^*-loxp/loxp*^ mice with PB-Cre4 (prostate-specific expression of Cre) mice. Genotyping of six mouse progenies for the PTEN locus (top panel) and the Cre transgene locus (bottom panel) using tail genomic DNA. (B) *PTEN*^*−/−*^ mice were castrated at 23 weeks old. Typical images of age-matched partial urogenital systems (bladder, prostatic lobes, seminal vesicles) from an intact and a castrated mouse are shown.Supplementary Figure 1Supplementary Figure 2Expression of MUC1 in bone PC metastases. IHC staining of PC bone metastases (*n* = 9) for both MUC1-N (N-terminal fragment) and MUC1-C (C-terminal fragment). Typical images for the indicated patients at a low- (scale bar: 2 mm) and high- (scale bar: 200 mm) power magnification are provided.Supplementary Figure 2Supplementary Figure 3The MUC1 network. The network was generated as described in our recent publication [@bb0085]. Briefly, the interactions were derived using the pathway and interaction data from HPRD, Reactome, NCI-Nature Cell Map. The network was constructed using the system provided by cBioPortal (http://www.cbioportal.org/).Supplementary Figure 3Supplementary Figure 4Genomic alterations in the eight MUC1 network genes within the nine-gene list associate with reductions in DSF and OS in patients with either PC or skin cutaneous melanoma. FAM84B gene was removed from the nine-gene set (APP, CTNNB1, GALNT10, GRB2, LYN, SIGLEC1, SOS1, ZAP70, and FAM84B). The specific genomic alterations (see [Table 3](#t0015){ref-type="table"} for details) in the remaining eight MUC1 network gene associate with decreases in DFS in PC (A) and cutaneous melanoma (C) as well as OS (B) in cutaneous melanoma. Genomic data were extracted from the TCGA cohorts of PC and skin cutaneous melanoma within the cBioPortal database.Supplementary Figure 4Supplementary Figure 5Mutations in β-catenin in D32, T41, and N387 significantly shorten overall survival in patients with metastatic prostate cancer. Data were extracted from the Michigan data set [@bb0110] (cBioPortal). (A) The three missense mutations and their associated OS are indicated. (B) Kaplan-Meier analysis of OS time in metastatic PCs with and without the missense mutations in β-catenin. Statistical analysis was performed using log-rank test. Both analyses were carried out using the tools provided by cBioPortal. Total\#, total number of cases; dec\#, number of deceased cases; MMS, median months survival.Supplementary Figure 5Supplementary Figure 6Genomic alterations in APC and β-catenin significantly associate with reductions in DFS in patients with PC. (A) Please see [Figure 5](#f0025){ref-type="fig"}*A* for the types of genomic alterations that occurred in APC and β-catenin in the TCGA data set (cBioPortal). Kaplan-Meier curve was constructed and log-rank test was performed using tools provided by cBioPortal. (B) Data were extracted from a subcohort from the MSKCC data set within the cBioPortal database [@bb0105] and analyzed for DFS using Kaplan-Meier curve and log-rank test. Total\#, total number of cases; relap\#, number of relapsed cases; MMDFS, median months disease-free survival.Supplementary Figure 6Supplementary Figure 7The nine-gene signature stratifies high- and low-risk groups of prostate cancer patients with respect to recurrence. (A) Scores of the nine-gene signature were assigned to individual patients based on the formula ∑(*f*~i~)*n*, (*f*~i~: Cox coefficient of individual factors, *n* = 9) (see [Supplementary Table 4](#ec0020){ref-type="supplementary-material"} for details). ROC curve was constructed using the pROC package in R. The data set used is the TCGA within cBioPortal. (B, C) Based on the scores ([Supplementary Table 4](#ec0020){ref-type="supplementary-material"}), the median (B) and Q3 scores (C) was used to stratify patients into high-risk (score positive) and low-risk groups (score negative), which were analyzed for the associated DFS times (Kaplan-Meier curve and log-rank test) using R statistics.Supplementary Figure 7Supplementary Figure 8Relationship of the nine-gene signature with BRCA1 and BRCA2 mutations. The indicated types of genomic alterations for the nine genes, BRCA1, and BRCA2 in the TCGA data set (*n* = 492) within the cBioPortal database are shown; only the proportion of cohorts containing the genomic alterations are included. Each column is for individual tumor. DF, disease free; NA, not available.Supplementary Figure 8Supplementary Table 1List of the MUC1 Network Genes and FAM84B Used in Variable SelectionSupplementary Table 1Supplementary Table 2Optimization of the Initial Selected 10 Genes^a^Supplementary Table 2Supplementary Table 3Prediction of PC Recurrence Using the Nine-Gene SignatureSupplementary Table 3Supplementary Table 4Events Analyzed by the Cox ModelSupplementary Table 4Supplementary Table 5Univariate and Multivariate Cox Regression Analysis of Individual Genes within the Nine-Gene List for PC RecurrenceSupplementary Table 5
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[^5]: Ratio of MUC1-positive cells in PAP-positive cells.
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[^8]: Genomic alterations are included only for the final set of genes. Amp, amplification; Mut, mutation; Homdel, homdeletion.

[^9]: Best HR, CI, and *P* value produced in 10 training sets.
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[^12]: The final set of genes or the nine-gene set.

[^13]: All cohorts were extracted from cBioPortal.

[^14]: Frequently mutated resides are bolded.

[^15]: *n*, number of patients; Mutation (*n*), number of cases with the indicated mutations.

[^16]: Patient ID is included only for patients with PC containing either T41A or missense mutations in D32 within the TCGA dataset.

[^17]: Number of cases.

[^18]: The nine-gene signature. 0: signature-negative; 1: signature-positive.

[^19]: Six cases without stage information.

[^20]: Radical prostatectomy Gleason score.
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